Barclays keeps Guardant Health overweight, raises target to $220
Barclays maintained its overweight rating on Guardant Health and raised its price target to $220 from $200, according to Benzinga ratings coverage.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.